Cargando…

The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin

Detalles Bibliográficos
Autores principales:	Miller, Aaron L., Rider, Nicholas L., Pyles, Richard B., Judy, Barbara, Xie, Xuping, Shi, Pei-Yong, Ksiazek, Thomas G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Academy of Allergy, Asthma & Immunology 2022
Materias:	Covid-19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023086/ https://www.ncbi.nlm.nih.gov/pubmed/35465974 http://dx.doi.org/10.1016/j.jaci.2022.03.026

Ejemplares similares

Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2
por: Ahn, Terrie S., et al.
Publicado: (2021)

Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID‐19: The GIMEMA EMATO‐0321 study
por: Marasco, Vincenzo, et al.
Publicado: (2022)

Les immunoglobulines anti-COVID en pédiatrie, pour qui, pourquoi, comment ?
por: Mershati, S. El, et al.
Publicado: (2023)

Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19
por: Pourahmad, Ramtin, et al.
Publicado: (2020)

Availability of Internationally Controlled Essential Medicines in the COVID-19 Pandemic
por: Pettus, Katherine, et al.
Publicado: (2020)

Assessing the availability and quality of COVID-19 mortality data in Europe: a comparative analysis
por: Marinković, Ivan, et al.
Publicado: (2023)

New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases
por: Assini, Andrea, et al.
Publicado: (2020)

Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern
por: Lafon, Eliott, et al.
Publicado: (2022)

Endothelial Cell–Activating Antibodies in COVID‐19
por: Shi, Hui, et al.
Publicado: (2022)

Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure
por: Muslim, Shahnawaz, et al.
Publicado: (2020)

“Palliative Pandemic Plan,” Triage and Symptoms Algorithm as a Strategy to Decrease Providers’ Exposure, While Trying to Increase Teams Availability and Guidance for Goals of Care (GOC) and Symptoms Control
por: Lopez, Santiago, et al.
Publicado: (2020)

COVID-19 antibody seroprevalence in Santa Clara County, California
por: Bendavid, Eran, et al.
Publicado: (2021)

Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel
por: Reicher, Shay, et al.
Publicado: (2021)

Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19
por: Cimolai, Nevio
Publicado: (2021)

Monoclonal antibody therapy for prevention of severe disease in nosocomial COVID-19
por: Zimilover, Adam, et al.
Publicado: (2022)

Current and Future Challenges in the Delivery of Mental Healthcare during COVID-19
por: Gautam, Mohan, et al.
Publicado: (2020)

Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms
por: Chowdhury, Onima, et al.
Publicado: (2021)

Bell’s palsy following COVID-19 vaccination with high CSF antibody response
por: Obermann, Mark, et al.
Publicado: (2021)

Prevalence of SARS-CoV-2 Antibody in Healthcare Workers in Central Pennsylvania
por: Kwon, Taesung, et al.
Publicado: (2021)

Is a “COVID-19-free” hospital the answer to resuming elective surgery during the current pandemic? Results from the first available prospective study
por: Gammeri, Emanuele, et al.
Publicado: (2020)

SARS-CoV-2-Related Kidney Injury: Current Concern and Challenges
por: Cheng, Yongqian, et al.
Publicado: (2020)

A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges
por: Hossen, Md. Shafiul, et al.
Publicado: (2020)

A review of ischemic stroke in COVID-19: currently known pathophysiological mechanisms
por: Tang, Xuhuan, et al.
Publicado: (2021)

ADEM anti-MOG antibody-positive after SARS-CoV2 vaccination
por: Mumoli, Laura, et al.
Publicado: (2021)

Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity
por: Delmonte, Ottavia M., et al.
Publicado: (2021)

Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study
por: Espenhain, Laura, et al.
Publicado: (2021)

A case of anti-MOG antibody-positive ADEM following COVID-19 mRNA vaccination
por: Miyamoto, Katsuichi, et al.
Publicado: (2022)

Antimicrobial Stewardship-Driven Monoclonal Antibody Treatment Program for COVID-19 Patients in the Bronx, New York
por: Guo, Yi, et al.
Publicado: (2021)

Adapting Vascular Surgery Practice to the Current COVID-19 Era at a Tertiary Academic Center in Madrid
por: Reyes Valdivia, Andrés, et al.
Publicado: (2020)

COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies
por: Passamonti, Francesco, et al.
Publicado: (2021)

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
por: Sauerwein, Kai M.T., et al.
Publicado: (2023)

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
por: Cervia, Carlo, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2 antibodies during the third wave of COVID-19 in the Seoul metropolitan area of Korea
por: Yoon, Kyuhyun, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 antibodies in the community based on participants in the 2020 Korea National Health and Nutrition Examination Survey
por: Kim, Ah-Ra, et al.
Publicado: (2022)

Prevalence and risk factors of SARS-CoV-2 antibody responses among healthcare workers (June 2020–November 2021)
por: Barrufet, Maria Pilar, et al.
Publicado: (2023)

Investigation of Anti-SARS-CoV-2 IgG and IgM Antibodies in the Patients with COVID-19 by Three Different ELISA Test Kits
por: Nagasawa, Masayuki, et al.
Publicado: (2020)

Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies
por: Bellinvia, Angelo, et al.
Publicado: (2022)

The Impact of Quarantines, Lockdowns, and ‘Reopenings’ on the Commercialization of Science: Micro and Macro Issues
por: Siegel, Donald S., et al.
Publicado: (2021)

Anti-SARS-Cov-2 IgA in Current Scenario of IgM and IgG Rapid Test: a New Alternative for the Diagnostic of COVID-19
por: La Rosa Fabián, Christian, et al.
Publicado: (2020)

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis following third dose of BNT162b2 COVID-19 vaccine in a patient with systemic lupus erythematosus
por: Kang, Minsung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_adkhsn3csme74rnlihrj53q40h